# Role of Serum ADAM 17 (A Disintegrin And Metalloprotease 17) and Caspase 3 in Patients With Chronic Kidney Disease

> **NCT06392425** · — · NOT_YET_RECRUITING · sponsor: **Assiut University** · enrollment: 90 (estimated)

## Conditions studied

- Chronic Kidney Diseases

## Interventions

- **OTHER:** caspase 3 and ADAM 17 biomarkers

## Key facts

- **NCT ID:** NCT06392425
- **Lead sponsor:** Assiut University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-04-26
- **Primary completion:** 2027-03-31
- **Final completion:** 2027-10-31
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2024-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06392425

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06392425, "Role of Serum ADAM 17 (A Disintegrin And Metalloprotease 17) and Caspase 3 in Patients With Chronic Kidney Disease". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT06392425. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*